Holen Sie sich die Stockscreener-App
14.37
4.09%
0.565
Handel nachbörslich:
14.40
0.035
+0.24%
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Two Sigma Advisers LP Sells 15,500 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - marketscreener.com
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - BioSpace
KalVista Pharmaceuticals to Present New Sebetralstat Data at the - GuruFocus
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KALV Stock News - GuruFocus
Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 - BioSpace
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - marketscreener.com
KalVista (KALV) Shows Promising Sebetralstat Results for Heredit - GuruFocus
KalVista (KALV) Shows Promising Sebetralstat Results for Hereditary Angioedema | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highligh - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management | KALV Stock News - GuruFocus
New Clinical Data: Revolutionary Oral HAE Treatment Stops Attacks in Under 20 Minutes, Transforms Patient Care - Stock Titan
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Deutsche Bank AG Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Jane Street Group LLC - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Northern Trust Corp Sells 13,205 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
(KALV) Proactive Strategies - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings - Business Wire
Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com
(KALV) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Has $54,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Dimensional Fund Advisors LP Acquires 89,001 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of “Buy” by Analysts - Defense World
Wells Fargo & Company MN Has $171,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
MetLife Investment Management LLC Lowers Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 11 - marketscreener.com
Analyzing Ratios: KalVista Pharmaceuticals Inc (KALV)’s Financial Story Unveiled - DWinneX
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
JPMorgan Chase & Co. Decreases Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Trading (KALV) With Integrated Risk Controls - news.stocktradersdaily.com
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Should investors be concerned about KalVista Pharmaceuticals Inc (KALV)? - uspostnews.com
KalVista Pharmaceuticals Inc [KALV] Shares Jump Approximately 27.74% Over the Year - knoxdaily.com
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - BioSpace
KalVista Pharmaceuticals Inc (KALV) stock analysis: A comprehensive overview - uspostnews.com
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):